China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index.

China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.".

China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end.

In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries.

China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement.

China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of ​​"inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine.

China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics.

Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities.

During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.